Pizotifen (Pizotyline)

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Sandomigran; Belgium: Sandomigran; Czech Republic: Sandomigran; Denmark: Sandomigrin; France: Sanmigran; Ireland: Sanomigran; Italy: Sandomigran; Luxembourg: Mosegor, Sandomigran; Netherlands: Sandomigran; Poland: Polomigran; Slovakia: Sandomigran; Spain: Mosegor, Sandomigrán; Sweden: Sandomigrin; UK: Pizotifen, Sanomigran.

North America

Canada: Sandomigran.

Latin America

Argentina: Sandomigrán; Brazil: Sandomigran.

Drug combinations


Pizotifen: C~19~H~21~NS. Mw: 295.44. (1) Piperidine, 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methyl-; (2) 4-(9,10-Dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine. CAS-15574-96-6 (1970).

Pharmacologic Category

Antimigraine Agents, Miscellaneous; Serotonin and Histamine Antagonist. (ATC-Code: N02CX01).

Mechanism of action

Mechanism of action in migraine prophylaxis not fully elucidated.

Therapeutic use

Migraine prophylaxis.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to pizotifen or any component of the formulation. Concurrent use of MAOIs. Gastric outlet obstruction (pyloroduodenal obstruction, stenosing pyloric ulcer).

Warnings and precautions

Anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention) limited (use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, benign prostatic hypertrophy, xerostomia, or visual problems, and in patients intolerant to anticholinergic agents, including tricyclic antidepressants, phenothiazines, or cyproheptadine). May cause CNS depression. Use with caution in cardiovascular disease, diabetes mellitus, narrow-angle glaucoma (may be exacerbated by cholinergic blockade), and in hepatic or renal impairment. Not for use in acute treatment of migraine attacks. Use with caution in myasthenia gravis (may be exacerbated by cholinergic blockade), and in obese patients. Effects may be potentiated when used with other sedative drugs or ethanol. Avoid abrupt discontinuation. Some patients may develop tolerance.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart